Introduction {#s1}
============

Tumors frequently activate genes whose expression is normally restricted to the testes ([@bib71]; [@bib3]; [@bib96]). Since the testes are immune-privileged, the protein products encoded by these genes can evoke an immune response when expressed in tumors ([@bib93]; [@bib70]; [@bib19]). Given this feature, these \~270 genes are collectively termed cancer/testis (CT) genes and their encoded proteins are known as CT antigens ([@bib79]). CT antigens have long been considered attractive targets for immunotherapy in a wide variety of cancers ([@bib99]; [@bib86]). In addition, recent work from multiple groups has found that many CT antigens can support neoplastic behaviors in tumor cells ([@bib22]). Specifically, CT antigens have been implicated in supporting mitotic progression, degradation of tumor suppressors, promoting DNA repair and thwarting apoptosis ([@bib98]; [@bib30]; [@bib9]; [@bib50]; [@bib62]; [@bib95]; [@bib57]; [@bib21]). Collectively, studies on CT antigen function over the last 15 years indicate that these proteins are not merely innocuous by-products of aberrant tumor gene expression programs, but rather integral agents of tumor growth and survival.

Using a large-scale, loss-of-function screening approach, our group previously identified the CT antigen, ZNF165, as essential for triple-negative breast cancer (TNBC) survival ([@bib50]). Depletion of ZNF165 in vitro or in vivo reduces survival of TNBC cells. Importantly, elevated ZNF165 mRNA expression correlates significantly with reduced survival time in breast cancer, indicating that expression of this protein may confer an aggressive tumorigenic phenotype ([@bib50]).

ZNF165 is a C~2~H~2~ zinc finger transcription factor that contains an N-terminal SCAN domain and six canonical Zn^2+^ fingers at its C-terminus. Consistent with its characterization as a CT antigen, ZNF165 expression is restricted to human testes and is extremely low or undetectable in normal breast tissues ([@bib88]; [@bib50]). Unfortunately, ZNF165 lacks conservation in mice, thereby precluding genetic studies that could illuminate its normal function within the testes ([@bib88]). However, investigation of its function in TNBC revealed that ZNF165 associates with chromatin to regulate expression of its target genes, which includes approximately 25% of all TGFβ-responsive genes in TNBC cells ([@bib50]).

The cellular response to TGFβ is highly context selective, often resulting in dramatically different phenotypes. For example, TGFβ is well known to facilitate growth inhibition in breast epithelia and most other somatic tissues, primarily through transcriptional activation of cyclin-dependent kinase inhibitors that result in cell cycle arrest ([@bib26]; [@bib63]; [@bib55]). Conversely, TGFβ has also been shown to stimulate the growth and differentiation of multiple cell types, including chondrocytes, hematopoietic stem cells, and endothelial cells ([@bib24]; [@bib40]; [@bib10]). These contrasting responses to TGFβ are generally dictated by cell type-specific transcription factors, which associate with TGFβ-responsive SMAD proteins (SMAD3 and SMAD4) and recruit them to appropriate target genes for transcriptional regulation ([@bib14]; [@bib23]; [@bib56]; [@bib49]). In TNBC, TGFβ induces a metastatic phenotype by promoting survival, chemoresistance, and the epithelial-to-mesenchymal transition ([@bib48]; [@bib8]). These processes are generally attributed to the activity of SMAD3, which binds directly to chromatin in a complex with SMAD4. Notably, SMAD3 expression is elevated in late-stage breast tumors compared to other receptor-activated SMADs ([@bib87]; [@bib59]; [@bib61]).

Here, we investigate the mechanisms by which ZNF165 modulates TGFβ-dependent transcription in TNBC. We find that ZNF165 co-occupies a subset of SMAD3 genomic binding sites and physically interacts with SMAD3 on chromatin, enhancing SMAD3 recruitment to specific loci. We also identify ZNF446 and TRIM27, two proteins never implicated in TGFβ signaling or TNBC, as critical components of the ZNF165-SMAD3 transcriptional complex. Importantly, loss of function of this complex, through genetic inhibition of TRIM27, attenuates growth of an orthotopic xenograft model of TNBC in vivo. These findings establish that anomalous expression of ZNF165 promotes the assembly of a neomorphic transcriptional complex that contributes to oncogenic TGFβ transcription in TNBC.

Results {#s2}
=======

SMAD3 is enriched at ZNF165 binding sites in TNBC cells {#s2-1}
-------------------------------------------------------

To comprehensively investigate whether ZNF165 interfaces with the TGFβ transcriptional network, we first generated a SMAD3 genomic binding profile in WHIM12 cells, where ZNF165 is essential for growth ([@bib50]). WHIM12 cells were originally developed from a patient-derived xenograft established from a triple-negative, highly chemo-resistant tumor ([@bib42]). Moreover, these cells are classified within the claudin-low molecular subtype of breast cancer, which exhibits activated TGFβ signaling ([@bib64]; [@bib2]; [@bib69]). We found that SMAD3 binding is associated with over \>27,000 sites in WHIM12 cells, comparable to previous studies of SMAD3 binding in TNBC cell lines ([@bib91]). Intersecting SMAD3 and ZNF165-associated genes revealed that \>90% of ZNF165 target genes are also bound by SMAD3, an overlap representing a statistically significant enrichment (p=5.5e-120, hypergeometric distribution) ([Figure 1A](#fig1){ref-type="fig"}). This is in agreement with our previous findings that ZNF165 targets a significant fraction of the TGFβ-responsive transcriptome ([@bib50]). Mapping the distance between binding sites further revealed that 90% of shared targets were bound by both transcription factors at a distance of less than 100 kb from one another ([Figure 1B](#fig1){ref-type="fig"}). Furthermore, 36% of shared target genes had ZNF165 and SMAD3 binding sites within 1 kb, a proximity at which both factors exhibited overlap on chromatin due to the broad enrichment profile of SMAD3 as observed within our dataset ([Figure 1B--E](#fig1){ref-type="fig"}). We next established ZNF165 and SMAD3 binding profiles in SUM159 cells, which are also classified within the claudin-low molecular subtype and require ZNF165 for viability ([@bib64]; [@bib50]). SMAD3 enrichment at the ZNF165 binding sites here closely resembled that of WHIM12 cells ([Figure 1C--E](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1A--C](#fig1s1){ref-type="fig"}). Further analysis of SMAD3 binding in MDA-MB-231 cells corroborated these findings ([Figure 1---figure supplement 1D--F](#fig1s1){ref-type="fig"}). Together these data demonstrate that despite differences in the genetic backgrounds of TNBC tumor cells, ZNF165 and SMAD3 exhibit significant co-occupancy on chromatin throughout the genome.

![SMAD3 is enriched at ZNF165 binding sites in TNBC cells.\
(**A**) Venn diagram displaying the overlap between ZNF165 and SMAD3 target genes in WHIM12 cells as identified by GREAT (ver 3.0.0). Significance was determined using the hypergeometric distribution. (**B**) Cumulative frequency distribution of the nearest distance between ZNF165 and SMAD3 binding sites associated with each shared target gene. Distance was calculated using the peak coordinates of each factor nearest to one another. (**C**) Browser tracks of ChIP-seq data showing peaks for ZNF165 and SMAD3 near the *CDC25B* and *BCAR1* loci with overlapping distances of 223 and 680 bp, respectively. (**W**) WHIM12, (**S**) SUM159. (**D**) Heatmaps of ChIP-seq data for ZNF165 and SMAD3 in the indicated TNBC cell lines. All peaks within each heatmap are centered ±2.5 kb from the ZNF165 peaks identified in WHIM12 cells (n = 322). (**E**) Normalized read density (per bp per peak) for SMAD3 plotted ±2.5 kb from the ZNF165-SMAD3 co-bound peaks identified in WHIM12 cells (n = 118). (**F**) Pie charts displaying the distribution of genomic features bound by ZNF165-SMAD3 (n = 118) or only SMAD3 (n = 27,979) in WHIM12 cells. (**G**) Motifs enriched at ZNF165-SMAD3 co-bound sites within WHIM12 cells. The 204 ZNF165 binding sites not occupied by SMAD3 were used as a control set of sequences to identify differentially enriched motifs at the shared sites (n = 118). (**H**) Motif density (per bp per peak) for the GCCG(G\|C)C motif plotted ±2.5 kb from the ZNF165-SMAD3 co-bound peaks in WHIM12 cells.](elife-57679-fig1){#fig1}

We identified 118 sites where ZNF165 and SMAD3 were bound within 1 kb of each other in WHIM12 cells ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"}). More than 50% of these ZNF165-SMAD3 co-bound sites were present in gene promoters (−1 kb or +100 base pairs from TSS) while the majority of SMAD3 binding sites were generally distributed across different genomic regions ([Figure 1F](#fig1){ref-type="fig"}). Motif enrichment analysis revealed a significant presence of GC-rich motifs at the ZNF165-SMAD3 co-bound regions (n = 118) compared to those bound by ZNF165 alone (n = 204) ([Figure 1G and H](#fig1){ref-type="fig"}). Such GC-rich SMAD binding elements (SBEs) have recently been characterized as universal binding sites for receptor-activated SMAD proteins, and SMAD3 can bind variants of these motifs with high affinity ([@bib47]). Thus, the GC-rich SMAD3 binding element may be an underlying genomic feature of the ZNF165-occupied sites that facilitates co-occupancy. Collectively, these data suggest that ZNF165 and SMAD3 may form cis-regulatory modules on chromatin to direct TGFβ-mediated gene expression in TNBC. In support of this notion, gene set enrichment analysis of ZNF165-responsive genes in WHIM12 cells revealed a significant enrichment of genes involved in the epithelial-to-mesenchymal transition (EMT), a SMAD3-dependent process that promotes metastasis in response to TGFβ signaling ([Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"}, [Supplementary file 2](#supp2){ref-type="supplementary-material"}; [@bib87]; [@bib101]; [@bib61]). Consistent with this, elevated ZNF165 expression in patients with breast cancer is associated with a greater metastatic potential (Hazard Ratio (HR) = 1.4; p=0.004) ([Figure 1---figure supplement 1H](#fig1s1){ref-type="fig"}).

ZNF165 and SMAD3 cooperate to modulate TGFβ-responsive gene expression {#s2-2}
----------------------------------------------------------------------

Given the enrichment of SMAD3 and ZNF165 at shared sites and their general proximity to one another on chromatin, we next asked whether these transcription factors cooperate to regulate expression of co-bound genes. We leveraged a previously generated gene expression data set of TGFβ responsiveness in WHIM12 cells ([@bib50]). Here, we assembled a set of 65 TGFβ-responsive genes that are co-bound by SMAD3 and ZNF165 ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). We then compared the impacts of ZNF165 and SMAD3 depletion on a subset of these genes. This analysis revealed a significant correlation (r = 0.52) between expression fold-changes in response to depletion of either transcription factor ([Figure 2A](#fig2){ref-type="fig"}). In particular, ZNF165 and SMAD3 were required to either activate or repress expression of the majority of shared target genes (quadrant I and III, [Figure 2A](#fig2){ref-type="fig"}). We also observed opposing effects of SMAD3 and ZNF165 on a smaller subset of genes, suggesting that in some cases, the activities of these two proteins may oppose one another (quadrant II and quadrant IV, [Figure 2A](#fig2){ref-type="fig"}).

![ZNF165 and SMAD3 cooperate to modulate TGFβ-responsive gene expression.\
(**A**) WHIM12 cells were transfected with siRNA for 48 hr, and qPCR was used to quantify relative expression (log~2~ fold change) of ZNF165-SMAD3 target genes upon depletion of ZNF165 (x-axis) or SMAD3 (y-axis). The Pearson correlation coefficient is indicated by r. Data are representative of four independent experiments. (**B**) WHIM12 cells were transfected with siRNA for 72 hr. Whole cell lysates were collected and immunoblotted for the indicated proteins. Data are representative of two independent experiments. (**C**) As in (**B**) except cells were transfected with siRNA targeting SMAD3. (**D**) SUM159 cells were transfected with siRNA for 32 hr and subjected to SMAD3 ChIP followed by qPCR using primers targeting the indicated binding sites. Fold enrichment was determined by dividing the percent input values for SMAD3 by those for IgG. Error bars represent mean ± SEM. P-values were calculated using an unpaired, two-tailed Student's t-test. Data are representative of four independent experiments. (**E**) SUM159 cells were transfected with siRNA for 32 hr and subjected to H3K27ac ChIP followed by qPCR using primers targeted to the *RRAD* promoter or a negative control region. Error bars represent mean + SEM. P-value was calculated using an unpaired, two-tailed Mann-Whitney test. Data are representative of four independent experiments. (**F**) SUM159 cells stably expressing ZNF165-V5 or control cDNA were subjected to H3K27ac ChIP followed by qPCR using primers targeted to the *RRAD* promoter or a negative control region. Error bars represent mean + SEM. P-value was calculated using an unpaired, two-tailed Mann-Whitney test. Data are representative of four independent experiments.](elife-57679-fig2){#fig2}

The observed expression changes in [Figure 2A](#fig2){ref-type="fig"} suggest two modes of regulation for ZNF165-SMAD3 targets. First, ZNF165 collaborates with SMAD3 to activate or oppose TGFβ-mediated gene expression changes (quadrant I and III, [Figure 2A](#fig2){ref-type="fig"}). Alternatively, ZNF165 can antagonize SMAD3-mediated activation or repression of shared target genes in response to TGFβ (quadrant II and IV, [Figure 2A](#fig2){ref-type="fig"}). The majority of genes fell into the former category, with *SMURF2* and *RRAD* being the two most responsive and were thus selected as archetypes for follow-up analysis. Importantly, we found that RRAD and SMURF2 protein accumulation corresponded to mRNA alterations upon ZNF165 or SMAD3 depletion ([Figure 2B and C](#fig2){ref-type="fig"}).

Given the observed collaborative function of ZNF165 and SMAD3 on target gene expression, we next asked whether their association with chromatin was cooperative. ZNF165 knockdown resulted in a \~ 50% reduction of SMAD3 enrichment at the ZNF165 binding sites proximal to both *SMURF2* and *RRAD* ([Figure 2D](#fig2){ref-type="fig"}). Importantly, SMAD3 binding at the promoter of *LBH*, a site not co-bound by ZNF165, was unaffected by ZNF165 depletion. SMAD3 commonly recruits the histone acetyltransferase, p300, to activate gene expression of its targets ([@bib18]; [@bib34]). Consistent with this, we observed a reduction of H3K27ac at the ZNF165-SMAD3 binding site proximal to *RRAD* in response to ZNF165 knockdown ([Figure 2E](#fig2){ref-type="fig"}). Conversely, an increase in H3K27ac was detected upon ZNF165 overexpression ([Figure 2F](#fig2){ref-type="fig"}). These findings suggest that ZNF165 is essential for recruitment of SMAD3 to shared target gene promoters and transcriptional activation.

We reasoned that the coordinated activity of ZNF165 and SMAD3 could modulate expression of genes required for tumorigenic phenotypes. Indeed, SMURF2 is a well characterized negative regulator of the TGFβ pathway whose expression is activated in a TGFβ-dependent, SMAD-independent manner by PI3K signaling ([@bib58]). Together with our previous findings, data presented here now indicate that ZNF165 coordinates SMAD3 to repress SMURF2 and thereby attenuate negative feedback of TGFβ signaling in TNBC ([@bib50]). In addition, a report from 2001 indicated that RRAD is sufficient to promote proliferation of breast tumor cells in vitro and in vivo ([@bib89]). Based on this observation, we investigated breast cancer gene expression data sets for clinical correlates with RRAD expression. In the mesenchymal subtype of TNBC, which is enriched for active TGFβ signaling and an EMT gene expression signature, RRAD expression correlated with reduced overall survival (HR = 2.31; p=0.04) and greater metastatic potential (HR = 3.18; p=0.05) ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}; [@bib39]). Conversely, in luminal tumors, which are traditionally ER^+^ and exhibit tumor-suppressive TGFβ signaling, RRAD expression correlated with improved overall survival (HR = 0.63; p=0.01) and no correlation was observed with distant metastasis free survival (HR = 1.12; p=0.55) ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}; [@bib60]; [@bib72]). Moreover, DepMap analysis revealed that RRAD perturbation generally leads to a reduction in 2D growth of TNBC cell lines, and we found that RRAD was essential for growth of SUM159 cells in soft agar ([Figure 2---figure supplement 1D and E](#fig2s1){ref-type="fig"}). However, we observed an enhanced growth phenotype in ER^+^ MCF7 cells, supporting the notion that TGFβ mediates tumor-suppressive phenotypes in more differentiated breast cancer cells and pro-tumorigenic effects in less differentiated cell types ([Figure 2---figure supplement 1F](#fig2s1){ref-type="fig"}; [@bib87]; [@bib48]). Collectively, these data suggest that ZNF165 is capable of directing SMAD3 recruitment to TGFβ-responsive target genes, whose altered expression can support malignant behaviors in the context of TNBC.

ZNF165 physically associates with SMAD3 in a TGFβ-dependent manner {#s2-3}
------------------------------------------------------------------

As ZNF165 appears to facilitate SMAD3 recruitment to chromatin, we asked whether these proteins physically associate. Interaction studies using co-expression/co-immunoprecipitation indicated an association between ZNF165 and SMAD3 ([Figure 3A](#fig3){ref-type="fig"}). In addition, we found that ZNF165 interacts with the active, phosphorylated form of SMAD3 on chromatin in SUM159 cells stably expressing ZNF165-V5 ([Figure 3B](#fig3){ref-type="fig"}). Activation of SMAD3 and its resulting nuclear translocation is dependent on the phosphorylation of its C-terminus by TGFβRI in response to TGFβ ([@bib49]). Thus, we employed the serine/threonine kinase inhibitor SB-431542, which selectively inhibits TGFβRI and downstream phosphorylation of SMAD3, to assess whether the ZNF165-SMAD3 interaction is dependent on pathway activation ([Figure 3C](#fig3){ref-type="fig"}; [@bib32]; [@bib49]). Proximity ligation assays (PLAs) in SUM159 cells treated with TGFβ revealed an endogenous association between ZNF165 and SMAD3, which was significantly diminished by pre-treatment with SB-431542 ([Figure 3D](#fig3){ref-type="fig"}). Furthermore, we found that endogenous ZNF165 and SMAD4 also interact in a TGFβ-dependent manner ([Figure 3E](#fig3){ref-type="fig"}). Importantly, ChIP-seq analysis did not reveal the presence of ZNF165 binding sites near the *SMAD3* or *SMAD4* gene loci ([@bib50]). This supports the notion that ZNF165 functions to influence SMAD3/4 transcriptional activity via physical association and not through regulation of SMAD3/4 gene expression itself. Taken together, these results indicate that in response to TGFβ, ZNF165 associates with phosphorylated SMAD3 to modulate the transcriptional output of TGFβ signaling in TNBC.

![ZNF165 physically associates with SMAD3 in a TGFβ-dependent manner.\
(**A**) Forty-eight hours after transfection with HA-SMAD3 and/or ZNF165-myc cDNA, HEK293T cells were subjected to immunoprecipitation with HA antibody. Immunoblotting was performed with indicated antibodies. Data are representative of two independent experiments. (**B**) ChIP was performed in SUM159 cells stably expressing ZNF165-V5 with antibodies against phosphorylated SMAD3 (Ser423/425) or IgG, and the precipitated material was immunoblotted with indicated antibodies. Data are representative of two independent experiments. (**C**) SUM159 cells were pre-treated with SB-431542 at the indicated concentrations for 15 min, followed by stimulation with 5 ng mL^−1^ TGFβ for 30 min. Immunoblotting was performed with indicated antibodies. Data are representative of two independent experiments. (**D**) Proximity ligation assays (PLAs) performed using antibodies against endogenous ZNF165 and SMAD3 in SUM159 cells, where either antibody alone was used as a negative control. Cells were pre-treated with 20 μM SB-431542 or DMSO for 15 min, followed by stimulation with 5 ng mL^−1^ TGFβ for 30 min. Scale bar, 10 μm. The mean PLA signal (number of foci per nucleus) is quantified (right), where each data point represents the mean signal calculated within one image. P-value was calculated using an unpaired, two-tailed Student's t-test. Ten images were used per condition and data are representative of three independent assays. (**E**) As in (**D**) except antibodies against endogenous ZNF165 and SMAD4 were used.](elife-57679-fig3){#fig3}

ZNF446 is an obligate component of the ZNF165-SMAD3 transcriptional complex {#s2-4}
---------------------------------------------------------------------------

We reasoned that ZNF165 and SMAD3 likely function within a multi-protein transcriptional complex to mediate gene expression changes in response to TGFβ. Therefore, we searched for additional ZNF165 interactors using proteomics data generated from a systematic yeast two-hybrid (Y2H) screening approach ([@bib68]). This search returned 48 putative ZNF165 interacting partners, 17 of which are likely transcriptional regulators based on the presence of known gene regulatory domains ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). To triage these candidates, we focused on those containing a SCAN ([S]{.ul}RE-ZBP, [C]{.ul}tfin51, [A]{.ul}W-1 and [N]{.ul}umber 18) domain, which is well-documented to mediate specific interactions among SCAN-zinc finger proteins (ZFPs) and the only domain within ZNF165 aside from its zinc finger array ([Figure 4A](#fig4){ref-type="fig"}; [@bib17]). We identified five putative interactors with SCAN domains and examined the consequences of their depletion on *SMURF2* expression. Of the proteins tested, ZNF446 and SCAND1 phenocopied the changes in gene expression observed for ZNF165 and SMAD3 in two TNBC cell lines ([Figure 4B](#fig4){ref-type="fig"}). Examination of their tumor expression patterns revealed that ZNF446 is upregulated in breast tumors, an increase that trends with reduced survival in the triple-negative enriched basal-like subtype of breast cancer (HR = 1.89; p=0.059) ([Figure 4---figure supplement 1A and B](#fig4s1){ref-type="fig"}; [@bib60]; [@bib80]). Moreover, we found that depletion of ZNF446 significantly reduced anchorage-independent growth of TNBC cells ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). Co-expression/co-immunoprecipitation assays confirmed that ZNF165 and ZNF446 interact and that deletion of the ZNF165 SCAN domain abrogates this association ([Figure 4C](#fig4){ref-type="fig"}). In addition, an endogenous interaction between ZNF165 and ZNF446 was detectable in TNBC tumor cell nuclear extracts, confirming these proteins interact in the relevant subcellular compartment ([Figure 4D](#fig4){ref-type="fig"}). We then employed the SMAD3/4 PLA assay described above and found that ZNF446 interacts with both SMAD3 and SMAD4 in a TGFβ-dependent fashion, similar to ZNF165 ([Figure 4E and F](#fig4){ref-type="fig"}).

![ZNF446 is an obligate component of the ZNF165-SMAD3 transcriptional complex.\
(**A**) ZNF165 interactors that contain a SCAN domain as identified from a systematic yeast two-hybrid screening approach ([interactome.dfci.harvard.edu](http://interactome.dfci.harvard.edu/)). A domain map of ZNF165 is shown above for reference. (**B**) Forty-eight hours after transfection with indicated siRNAs, RNA was extracted from WHIM12 or SUM159 cells and qPCR was used to determine the relative expression of SMURF2. Log~2~ fold-change values normalized to control knockdown samples are displayed. Error bars represent mean + SEM. P-values were calculated for each sample using a one-tailed Mann-Whitney test. Data are representative of three independent experiments. (**C**) Forty-eight hours after transfection with indicated cDNA, HEK293T lysates were subjected to immunoprecipitation with V5 antibody. Immunoblotting was performed with indicated antibodies. Data are representative of three independent experiments. (**D**) SUM159 nuclear lysates were immunoprecipated with antibodies against endogenous ZNF165 or IgG. Immunoblotting was performed with indicated antibodies. Data are representative of two independent experiments. (**E**) Proximity ligation assays (PLAs) performed using antibodies against endogenous ZNF446 and SMAD3 in SUM159 cells, where either antibody alone was used as a negative control. Cells were pre-treated with 20 μM SB-431542 or DMSO for 15 min, followed by stimulation with 5 ng mL^−1^ TGFβ for 30 min. Scale bar, 10 μm. The mean PLA signal (number of foci per nucleus) is quantified (right), where each data point represents the mean signal calculated within one image. P-value was calculated using an unpaired, two-tailed Student's t-test. Ten images were used per condition and data are representative of three independent assays. (**F**) As in (**E**) except antibodies against endogenous ZNF446 and SMAD4 were used.](elife-57679-fig4){#fig4}

To determine if ZNF446 also associates with ZNF165-SMAD3 target genes, we performed ChIP-seq for ZNF446-V5 stably expressed in WHIM12 and SUM159 cells. This led to the identification of 5039 and 7926 binding sites in WHIM12 and SUM159 cells, respectively. In both cell lines, ZNF446 was enriched at the ZNF165 binding sites ([Figure 5A and B](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1A--C](#fig5s1){ref-type="fig"}). Intersecting the target genes identified for ZNF446 and ZNF165 further revealed a statistically significant overlap in both WHIM12 and SUM159 cells (p\<0.0001, hypergeometric distribution) ([Figure 5C and D](#fig5){ref-type="fig"}). Approximately half of all ZNF446 binding sites in WHIM12 cells were also co-occupied by SMAD3 ([Figure 5E and F](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}). These co-bound sites were largely enriched for promoter regions compared to the total binding sites for either factor ([Figure 5---figure supplement 1E](#fig5s1){ref-type="fig"}). Differential motif enrichment analysis revealed the presence of a short GC-rich element at these ZNF446-SMAD3 bound sites, closely resembling the motif we identified at ZNF165-SMAD3 bound sites and identical to the recently reported SMAD consensus binding motif ([Figure 5G and H](#fig5){ref-type="fig"}; [Figure 1G](#fig1){ref-type="fig"}; [@bib47]). In addition, we found that over half of the TGFβ-responsive target genes shared by ZNF165 and SMAD3 (251/446) are also targeted by ZNF446 ([Figure 5I](#fig5){ref-type="fig"}). The impact of ZNF446 depletion on expression of these genes significantly correlated with both ZNF165 (r = 0.49) and SMAD3 (r = 0.86) ([Figure 5J](#fig5){ref-type="fig"}). Together, these findings collectively implicate ZNF446 as a member of the ZNF165-SMAD3 complex that can influence TGFβ-dependent gene regulation in TNBC.

![ZNF446 co-occupies a subset of ZNF165 and SMAD3 binding sites in TNBC cells.\
(**A**) Heatmaps of ChIP-seq data for ZNF165 and ZNF446 in the indicated TNBC cell lines. All peaks within each heatmap are centered ±2.5 kb from the WHIM12 ZNF165 peaks (n = 322). (**B**) Normalized read density (per bp per peak) for ZNF446 plotted ±2.5 kb from the ZNF165 peaks identified in WHIM12 cells (n = 322). (**C**) Venn diagram displaying the overlap between ZNF165 and ZNF446 target genes in WHIM12 cells as identified by GREAT (ver 3.0.0). P-value (p\<0.0001) was calculated using the hypergeometric distribution. (**D**) As in (**C**) except using target genes identified for ZNF165 and ZNF446 in SUM159 cells. (**E**) Heatmaps of ChIP-seq data for ZNF446 and SMAD3 in WHIM12 cells. All peaks within each heatmap are centered ±2.5 kb from the ZNF446 peaks (n = 5,039). (**F**) Read density (per bp per peak) for SMAD3 plotted ±2.5 kb from the ZNF446 peaks identified in WHIM12 cells (n = 5,039). (**G**) Motifs enriched at ZNF446-SMAD3 co-bound sites within WHIM12 cells. The ZNF446 binding sites not occupied by SMAD3 (n = 2,587) were used as a control set of sequences to identify differentially enriched motifs at the shared sites (n = 2,376). (**H**) Motif density (per bp per peak) for the (G\|C)CGCGG motif plotted ±2.5 kb from the ZNF446-SMAD3 co-bound peaks in WHIM12 cells. (**I**) Venn diagram displaying the overlap between ZNF165, SMAD3, and ZNF446 target genes from WHIM12 cells as identified by GREAT (ver 3.0.0). (**J**) Heatmap displaying log~2~ fold-changes of ZNF165-SMAD3 targets in response to depletion of ZNF446, as well as either ZNF165 or SMAD3. The Pearson correlation coefficient is indicated by r. Significance is indicated by asterisks, where \*=p \< 0.05 and \*\*\*\*=p \< 0.0001. Data are representative of four independent experiments.](elife-57679-fig5){#fig5}

TRIM27 is essential for ZNF165 transcriptional activity and tumor growth in vivo {#s2-5}
--------------------------------------------------------------------------------

ZNF446 contains a KRAB (Krüppel-associated box) domain, which is well documented to interact with the RBCC (RING, B-box, coiled-coil) domain of proteins within the tripartite motif (TRIM) family that in turn function as co-repressors or, as recently demonstrated, co-activators ([@bib20]; [@bib74]; [@bib75]; [@bib15]). Y2H-based proteomics confirmed such an interaction of TRIM27, which contains the classic RBCC domain, with ZNF446 ([Figure 6A](#fig6){ref-type="fig"}; [Supplementary file 3](#supp3){ref-type="supplementary-material"}). Originally identified as an oncogenic fusion with the RET tyrosine kinase, TRIM27 has been ascribed roles in numerous cellular processes that include transcriptional repression, proliferation, meiosis, innate immunity, and endosomal trafficking ([@bib83]; [@bib77]; [@bib78]; [@bib104]; [@bib27]; [@bib103]; [@bib107]; [@bib45]). However, its function as a transcriptional regulator in TNBC has not been characterized. Co-expression/co-immunoprecipitation experiments revealed that both ZNF446 and ZNF165 interact with TRIM27 and that all three proteins immunoprecipitate as a complex ([Figure 6B](#fig6){ref-type="fig"}). We subsequently confirmed a nuclear interaction between ZNF165-V5 and endogenous TRIM27 by proximity ligation in SUM159 cells and found that TRIM27 depletion also phenocopied changes in ZNF165-SMAD3 target gene expression (r = 0.81) ([Figure 6C and D](#fig6){ref-type="fig"}). Notably, TRIM27 appears to be bi-functional, either positively or negatively regulating expression of the ZNF165-SMAD3 targets (quadrant I and III, [Figure 6D](#fig6){ref-type="fig"}). Indicative of a co-activator function, we found that TRIM27 is required for the transcriptional activation of *RRAD* following ZNF165 or ZNF446 overexpression ([Figure 6E](#fig6){ref-type="fig"}; [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). Similar to ZNF165 and ZNF446, proximity ligation assays revealed endogenous, nuclear interactions between TRIM27 and both SMAD3 and SMAD4, which were reduced by TGFβ pathway inhibition ([Figure 6F and G](#fig6){ref-type="fig"}).

![TRIM27 is essential for ZNF165 transcriptional activity and tumor growth in vivo.\
(**A**) Cartoon maps showing the domains of ZNF446 and TRIM27. The KRAB-binding domain of TRIM27 is highlighted for reference. (**B**) Forty-eight hours after transfection with indicated cDNA, HEK293T lysates were subjected to immunoprecipitation with HA antibody. Immunoblotting was performed using indicated antibodies. Data are representative of three independent experiments. (**C**) Proximity ligation assays (PLAs) performed using V5 and TRIM27 antibodies in SUM159 cells stably expressing ZNF165-V5. Parental SUM159 cells were used as a negative control with the V5/TRIM27 antibody combination. Scale bar, 10 μm. The mean PLA signal (number of foci per nucleus) is quantified (right), where each data point represents the mean signal calculated within one image. P-values were calculated using an unpaired, two-tailed Student's t-test. Five images were used per condition and data are representative of four independent assays. (**D**) WHIM12 cells were transfected with siRNA for 48 hr and qPCR was used to quantify relative expression (log~2~ fold change) of shared ZNF165-SMAD3 target genes upon depletion of ZNF165 (x-axis) or TRIM27 (y-axis). The Pearson correlation coefficient is indicated by r. Data are representative of three independent experiments. (**E**) SUM159 cells stably expressing indicated cDNA were transfected with siRNA targeting TRIM27 for 48 hr. Relative RRAD expression was measured using qPCR and the data were normalized to the CTRL sample (grey). Error bars represent mean + SEM. P-values were calculated using an unpaired, two-tailed Mann-Whitney test. Significance is indicated by asterisks, where \*=p \< 0.05. Data are representative of four independent experiments. (**F**) PLAs performed using antibodies against endogenous TRIM27 and SMAD3 in SUM159 cells, where either antibody alone was used as a negative control. Cells were pre-treated with 20 μM SB-431542 or DMSO for 15 min, followed by stimulation with 5 ng mL^−1^ TGFβ for 30 min. Scale bar, 10 μm. The mean PLA signal (number of foci per nucleus) is quantified (right), where each data point represents the mean signal calculated within one image. P-value was calculated using an unpaired, two-tailed Student's t-test. Ten images were used per condition and data are representative of three independent assays. (**G**) As in (**F**) except antibodies against endogenous TRIM27 and SMAD4 were used. (**H**) Tumor volumes from mice orthotopically injected with SUM159T-Luciferase cells stably expressing shRNAs against TRIM27 (n = 10) or a non-targeting control (n = 9). P-value was calculated using an unpaired, two-tailed Student's t-test. (**I**) Representative images of bioluminescence (BLI) measurements taken for mice from each group. BLI data was quantified (right) and the p-value was calculated using an unpaired, two-tailed Student's t-test.](elife-57679-fig6){#fig6}

TRIM27 expression is elevated in several cancers including colon, lung, endometrial and ovarian, and often correlates with poor prognosis ([@bib90]; [@bib29]; [@bib33]; [@bib108]; [@bib45]; [@bib106]). Using TCGA data, we found that TRIM27 expression is significantly elevated in TNBC compared to normal breast tissue ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). Moreover, we stained a small cohort of normal and TNBC tissues for TRIM27 and observed a striking difference in its subcellular localization. TRIM27 appeared to be predominantly cytoplasmic in normal breast epithelia and more nuclear in TNBC tissues, suggesting that its transcriptional activity might associate with the transformed state ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). This finding is in agreement with previous reports and the Human Tissue Atlas, where TRIM27 is mostly cytoplasmic in normal breast and nuclear in testis and a subset of breast cancer tissues ([@bib84]; [@bib85]; [@bib92]).

Given that TRIM27 was critical for ZNF165-dependent gene regulation, we next asked whether TRIM27 was essential for malignant behaviors. In the absence of extracellular matrix, TRIM27 depletion dramatically reduced tumor cell growth ([Figure 6---figure supplement 1D--F](#fig6s1){ref-type="fig"}). We next perturbed TRIM27 as a means to inhibit the activity of the ZNF165 transcriptional complex and assess its impact on TNBC tumor growth and survival at the orthotopic site in mice. Following stable depletion of TRIM27, SUM159 cells were injected into the mammary fat pad of immunocompromised mice ([Figure 6---figure supplement 1E](#fig6s1){ref-type="fig"}). We observed a significant decrease in tumor size, suggesting that TRIM27 is essential for TNBC tumor growth in vivo and that inhibition of the ZNF165 transcriptional complex may be a promising avenue of therapeutic intervention ([Figure 6H and I](#fig6){ref-type="fig"}). Together, these results indicate that TRIM27 is a previously unrecognized regulatory component of TGFβ signaling in TNBC and functions to modulate TGFβ-dependent transcription in cooperation with ZNF165, ZNF446, and SMAD3.

Discussion {#s3}
==========

Striking similarities between tumors and developing germ cells have been noted for over a century ([@bib79]). As a result, it has been speculated that a fundamental attribute of cancer is the usurpation of developmental signaling programs. Tumors frequently activate expression of gametogenic genes, which encode a group of proteins termed cancer/testis antigens (CT antigens) ([@bib13]; [@bib79]). While these proteins have long been considered optimal targets for immunotherapy, their function, if any, in tumor cells has not been well-established.

In recent years, an increasing number of studies have begun to indicate that CT antigens are not merely innocuous by-products of aberrant gene expression programs, but instead can be essential to the progression of cancer. The list of tumor cell mechanisms regulated by these proteins includes mitosis, protein turnover, mitigating DNA damage, and disrupting normal transcriptional programs ([@bib22]). This variety of biological processes is attributable to the high degree of diversity in the functions of proteins classified as CT antigens, and speaks to the ability of tumor cells to engage aberrant gene expression programs in order to support their growth and survival. In support of this, our study of the testis protein ZNF165 has revealed a previously unrecognized mechanism by which TGFβ signaling is co-opted to promote malignancy in late-stage breast tumors.

Our findings expose a high degree of flexibility in tumor cell transcriptional networks. We reason that this feature could be the result of the modular domains present in many transcriptional regulators, particularly zinc finger proteins (ZFPs), which make up the largest family of transcription factors in the human genome ([@bib35]). The vast majority of these proteins contain KRAB, BTB/POZ, or SCAN domains, that mediate interactions with transcriptional partners ([@bib7]; [@bib5]; [@bib1]; [@bib100]). The SCAN domain in particular regulates the assembly and thus function of specific transcriptional complexes ([@bib17]). SCAN domains are not promiscuous, but demonstrate selectivity for co-association, the basis of which is not clear. Nevertheless, ectopic introduction of a SCAN domain-containing protein, such as ZNF165, may drive assembly of a neomorphic transcriptional complex, ZNF165-ZNF446-SMAD3-TRIM27, that is otherwise not present in somatic cells ([Figure 7](#fig7){ref-type="fig"}). This finding highlights the importance of silencing lineage-specific transcription factors, as their anomalous expression may be sufficient to disrupt transcriptional networks that regulate tissue homeostasis.

![Model for assembly of a neomorphic ZNF165 transcriptional complex in TNBC.\
Aberrant expression of testis-specific ZNF165 in TNBC co-opts somatic transcriptional machinery to modulate TGFβ-dependent transcription. The ZNF165 SCAN domain mediates interaction with ZNF446, and together these factors associate with SMAD3 at shared binding sites throughout the genome and alter gene expression to promote neoplastic behaviors. Via its KRAB domain, ZNF446 likely recruits the co-activator/co-repressor TRIM27, which is essential for ZNF165 transcriptional activity and tumor growth in vivo. Given the testis/tumor-restricted expression of ZNF165, disruption of this complex holds potential as a therapeutic strategy to specifically inhibit pro-tumorigenic TGFβ signaling in TNBC.](elife-57679-fig7){#fig7}

The study of CT antigen function generally, and ZNF165 in particular, has the capacity to reveal new principles underlying tumor cell regulatory networks. Specifically, our data indicate that both ZNF446 and TRIM27 are complicit in the activation of oncogenic TGFβ signaling in TNBC. While ZNF446 has been reported to act as a transcriptional repressor for SRF and AP-1 via its KRAB domain, a physiological function for ZNF446 in either normal or malignant contexts has not been reported ([@bib43]). Our findings suggest that in addition to functioning as a chromatin-bound cofactor for ZNF165 and SMAD3, ZNF446 may recruit TRIM27 to modulate TGFβ-induced transcription in TNBC. An important caveat to this conclusion is that the transcriptional effects we observed are based on changes in steady-state mRNA levels, a fraction of which could conceivably be due to post-transcriptional effects, a possibility that we did not fully rule out. Regardless, we find that ZNF446 and TRIM27 can either activate or repress expression of genes targeted by the ZNF165-SMAD3 complex, despite reports describing only repressive capabilities for these factors ([@bib77]; [@bib78]; [@bib43]). This finding also dovetails with a recent report demonstrating that TRIM28 serves as a co-activator for ZFP30-mediated adipogenesis, and together these studies begin to establish that tripartite motif proteins may be bi-functional with respect to transcriptional repression or activation ([@bib15]). Notably, TRIM27 is also a well characterized E3 ligase and has been reported to modify numerous protein substrates via ubiquitination and SUMOylation ([@bib16]; [@bib109]; [@bib38]). Future studies to address whether the catalytic activity of TRIM27 is required for ZNF165-dependent transcriptional regulation are therefore crucial, as small molecule inhibitors of TRIM27 could selectively disrupt pro-tumorigenic TGFβ signaling in TNBC.

An additional, unexpected finding is that *RRAD*, whose transcription is highly regulated by the ZNF165 transcriptional complex, is a TGFβ target gene that can exert opposing behaviors depending on context. TGFβ signaling is well known to drive pro-tumorigenic phenotypes in less differentiated breast tumor cell types, such as TNBC, while facilitating tumor suppression in more differentiated cell types ([@bib87]; [@bib48]). Our study indicates that RRAD contributes to such context-specific phenotypes conferred by TGFβ signaling, which may help to explain extensive data that report opposing impacts of RRAD expression in a variety of cancer types ([@bib82]; [@bib37]; [@bib54]; [@bib102]). With respect to function, RRAD is a small GTPase reported to negatively regulate L-type calcium channels in the heart, where its deficiency can promote cardiac hypertrophy ([@bib12]; [@bib46]; [@bib53]). In cancer, RRAD has been implicated in numerous processes, including the regulation of glycolysis, proliferation, NF-κB signaling, and apoptosis ([@bib37]; [@bib102]; [@bib31]; [@bib105]; [@bib44]; [@bib76]). Although the exact function of RRAD in TNBC will need to be elucidated in future studies, the vast array of phenotypes associated with this protein undoubtedly reflect the context within which it functions. Ultimately, further investigation could indicate that RRAD itself is a tractable intervention point in TNBC.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                Designation                                   Source or\                  Identifiers                                                                                Additional\
  (species) or\                                                                              reference                                                                                                              information
  resource                                                                                                                                                                                                          
  -------------------------------------------- --------------------------------------------- --------------------------- ------------------------------------------------------------------------------------------ ----------------------------------------------------------------
  Strain, strain background (*Mus musculus*)   NOD.Cg-*Prkdc^scid^Il2rg^tm1Wjl^*/SzJ; NSG    The Jackson Laboratory      Stock no. 005557; RRID:[IMSR_JAX:005557](https://scicrunch.org/resolver/IMSR_JAX:005557)   

  Cell line (*Homo sapiens*)                   HEK293T                                       ATCC                        CRL-3216; RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)                       

  Cell line (*H. sapiens)*                     MCF7                                          ATCC                        HTB-22; RRID:[CVCL_0031](https://scicrunch.org/resolver/CVCL_0031)                         

  Cell line (*H. sapiens)*                     WHIM12                                        [@bib42]                                                                                                               

  Cell line (*H. sapiens*)                     SUM159                                        Asterand                    RRID:[CVCL_5423](https://scicrunch.org/resolver/CVCL_5423)                                 

  Cell line (*H. sapiens*)                     SUM159T-Luciferase                            [@bib97]                                                                                                               

  Antibody                                     anti-HA (Rat monoclonal)                      Roche                       Cat \#11867423001; RRID:[AB_390918](https://scicrunch.org/resolver/AB_390918)              IB (1:1000), IP (1 μg)

  Antibody                                     anti-c-Myc (Rabbit polyclonal)                Santa Cruz Biotechnology    sc-789; RRID:[AB_631274](https://scicrunch.org/resolver/AB_631274)                         IB (1:1000)

  Antibody                                     anti-V5 (Rabbit monoclonal)                   Cell Signaling Technology   Cat \#13202; RRID:[AB_2687461](https://scicrunch.org/resolver/AB_2687461)                  IB (1:1000)

  Antibody                                     anti-SMAD3 (Rabbit polyclonal)                Abcam                       ab28379; RRID:[AB_2192903](https://scicrunch.org/resolver/AB_2192903)                      IB (1:1000), PLA (1:200), ChIP-qPCR (1.5 μg), ChIP-seq (10 μg)

  Antibody                                     anti-phospho-SMAD3 (Rabbit monoclonal)        Cell Signaling Technology   Cat \#9520; RRID:[AB_2193207](https://scicrunch.org/resolver/AB_2193207)                   IB (1:1000), ChIP (5 μg)

  Antibody                                     anti-SMURF2 (Mouse monoclonal)                Santa Cruz Biotechnology    sc-393848                                                                                  IB (1:500)

  Antibody                                     anti-RRAD (Goat polyclonal)                   Thermo Fisher Scientific    PA537885; RRID:[AB_2554493](https://scicrunch.org/resolver/AB_2554493)                     IB (1:1000)

  Antibody                                     anti-ZNF165 (Mouse monoclonal)                Novus Biologicals           H00007718-M02; RRID:[AB_1717273](https://scicrunch.org/resolver/AB_1717273)                IB (1:1000)

  Antibody                                     anti-ZNF165 (Rabbit polyclonal)               Atlas Antibodies            HPA007247; RRID:[AB_2797217](https://scicrunch.org/resolver/AB_2797217)                    IB (1:1000), PLA (1:200), IP (5 μg)

  Antibody                                     anti-Tubulin (Rabbit monoclonal)              Cell Signaling Technology   Cat \#2128; RRID:[AB_823664](https://scicrunch.org/resolver/AB_823664)                     IB (1:1000)

  Antibody                                     anti-ZNF446 (Rabbit polyclonal)               Proteintech                 16218--1-AP                                                                                IB (1:1000), PLA (1:200)

  Antibody                                     anti-TRIM27 (Rabbit monoclonal)               Cell Signaling Technology   Cat \#15099; RRID:[AB_2798707](https://scicrunch.org/resolver/AB_2798707)                  IB (1:1000)

  Antibody                                     anti-V5 (Mouse monoclonal)                    Thermo Fisher Scientific    R960-25; RRID:[AB_2556564](https://scicrunch.org/resolver/AB_2556564)                      PLA (1:500), IP (1 μg)

  Antibody                                     anti-SMAD3 (Mouse monoclonal)                 Santa Cruz Biotechnology    sc-101154; RRID:[AB_1129525](https://scicrunch.org/resolver/AB_1129525)                    PLA (1:200)

  Antibody                                     anti-SMAD4 (Mouse monoclonal)                 Santa Cruz Biotechnology    sc-7966; RRID:[AB_627905](https://scicrunch.org/resolver/AB_627905)                        PLA (1:200)

  Antibody                                     anti-TRIM27 (Rabbit polyclonal)               Proteintech                 12205--1-AP; RRID:[AB_2256660](https://scicrunch.org/resolver/AB_2256660)                  PLA (1:200), IHC (1:200)

  Antibody                                     anti-H3K27ac (Rabbit polyclonal)              Abcam                       ab4729; RRID:[AB_2118291](https://scicrunch.org/resolver/AB_2118291)                       ChIP-qPCR (2 μg)

  Antibody                                     Normal rabbit IgG (Rabbit polyclonal)         Cell Signaling Technology   Cat \#2729; RRID:[AB_1031062](https://scicrunch.org/resolver/AB_1031062)                   IP (1 μg), ChIP-qPCR (1.5--5 μg)

  Antibody                                     anti-V5 (Rabbit polyclonal)                   Abcam                       ab9116; RRID:[AB_307024](https://scicrunch.org/resolver/AB_307024)                         ChIP-seq (5 μg)

  Peptide, recombinant protein                 Human Transforming Growth Factor-β1           Cell Signaling Technology   Cat \#8915                                                                                 

  Chemical compound, drug                      SB-431542                                     Tocris Bioscience           Cat \#1614                                                                                 

  Commercial assay or kit                      KAPA HyperPrep Kit                            KAPA Biosystems             KK8502                                                                                     

  Commercial assay or kit                      Duolink In Situ PLA Probe Anti-Mouse PLUS     Sigma-Aldrich               DUO92001; RRID:[AB_2810939](https://scicrunch.org/resolver/AB_2810939)                     

  Commercial assay or kit                      Duolink In Situ PLA Probe Anti-Rabbit MINUS   Sigma-Aldrich               DUO92005; RRID:[AB_2810942](https://scicrunch.org/resolver/AB_2810942)                     

  Commercial assay or kit                      Duolink In Situ Detection Reagent Red         Sigma-Aldrich               DUO92008                                                                                   

  Software, algorithm                          ImageJ (Fiji)                                 [@bib73]                    RRID:[SCR_002285](https://scicrunch.org/resolver/SCR_002285)                               ver 2.0.0

  Software, algorithm                          Bowtie2                                       [@bib36]                    RRID:[SCR_005476](https://scicrunch.org/resolver/SCR_005476)                               ver 2.3.2

  Software, algorithm                          SAMtools                                      [@bib41]                    RRID:[SCR_002105](https://scicrunch.org/resolver/SCR_002105)                               ver 1.6

  Software, algorithm                          DeepTools                                     [@bib65]                    RRID:[SCR_016366](https://scicrunch.org/resolver/SCR_016366)                               ver 2.3.5

  Software, algorithm                          Integrative Genomics Viewer                   [@bib67]                    RRID:[SCR_011793](https://scicrunch.org/resolver/SCR_011793)                               ver 2.3.93

  Software, algorithm                          HOMER                                         [@bib28]                    RRID:[SCR_010881](https://scicrunch.org/resolver/SCR_010881)                               ver 4.9

  Software, algorithm                          GREAT                                         [@bib51]                    RRID:[SCR_005807](https://scicrunch.org/resolver/SCR_005807)                               ver 3.0.0

  Software, algorithm                          MEME                                          [@bib4]                     RRID:[SCR_001783](https://scicrunch.org/resolver/SCR_001783)                               ver 5.1.1

  Software, algorithm                          GSEA                                          [@bib81]                    RRID:[SCR_003199](https://scicrunch.org/resolver/SCR_003199)                               ver 4.0.3
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell lines and transfections {#s4-1}
----------------------------

Cell lines were obtained from American Type Culture Collection (ATCC) except for: WHIM12 (Matthew Ellis, Baylor College of Medicine), SUM159 (Asterand), and SUM159T-Luceiferase (Gray Pearson, Georgetown University). All cell lines were cultured in the provider's recommended medium and authenticated using short-tandem repeat (STR) profiling. Cell lines were regularly tested for mycoplasma and no contamination was observed. For siRNA transfections, cells were trypsinized and seeded in Opti-MEM containing Lipofectamine RNAiMAX (Thermo Fisher Scientific, Waltham, MA) and pooled siRNAs at a final concentration of 50 nM. cDNA transfections in HEK293T cells were performed using the calcium phosphate method as previously described ([@bib50]).

Antibodies and reagents {#s4-2}
-----------------------

The following antibodies were used for immunoblotting: HA (3F10; 1:1000; Roche, Basel, Switzerland), c-Myc (sc-789; 1:1000; Santa Cruz Biotechnology; Dallas, TX), V5 (13202; 1:1000; Cell Signaling Technology, Danvers, MA), SMAD3 (ab28379; 1:1000; Abcam, Cambridge, United Kingdom), phospho-SMAD3 (9520, 1:1000; Cell Signaling Technology), SMURF2 (sc-393848; 1:500; Santa Cruz Biotechnology), RRAD (PA537885; 1:1000; Thermo Fisher Scientific), ZNF165 (H00007718-M02; 1:1000; Novus Biologicals, Centennial, CO), ZNF165 (HPA007247, 1:1000; Atlas Antibodies, Bromma, Sweden), Tubulin (2128; 1:1000; Cell Signaling Technology), ZNF446 (16218--1-AP; 1:1000; Proteintech, Rosemont, IL), TRIM27 (15099; 1:1000; Cell Signaling Technology). The following antibodies were used for proximity ligation assays: V5 (R960-25; 1:500; Thermo Fisher Scientific), SMAD3 (ab28379; 1:200; Abcam), SMAD3 (sc-101154, 1:200; Santa Cruz Biotechnology), SMAD4 (sc-7966; 1:200, Santa Cruz Biotechnology), ZNF165 (HPA007247, 1:200; Atlas Antibodies), ZNF446 (16218--1-AP; 1:200; Proteintech), TRIM27 (12205--1-AP; 1:200, Proteintech). ChIP-qPCR experiments were performed with 1.5 μg SMAD3 (ab28379; Abcam; Lot no. GR321957-8), 5 μg phospho-SMAD3 (9520; Cell Signaling Technology; Lot no. 15), 2 μg H3K27ac (ab4729; Abcam; Lot no. GR323132-1), or the appropriate amount of normal rabbit IgG (2729; Cell Signaling Technology; Lot no. 9). ChIP-seq in WHIM12 and SUM159 cells was performed with 10 μg SMAD3 (ab28379; Abcam; Lot no. GR321957-8) or 5 μg V5 (ab9116; Abcam; Lot no. GR3215823-1). Immunoprecipitations used for interaction studies were performed with HA (3F10; Roche), V5 (R960-25; Thermo Fisher Scientific), and ZNF165 (HPA007247; Atlas Antibodies). IHC was performed using TRIM27 (12205--1-AP; Proteintech) at 1:200.

Transforming growth factor-β1 was purchased from Cell Signaling Technology (8915) and SB-431542 was purchased from Tocris Bioscience (Bristol, United Kingdom) (1614). siRNAs targeting ZNF165, SMAD3, ZNF446, TRIM27, SCAND1, ZNF24, ZNF263, or ZKSCAN8, and non-targeting control \#2 were obtained from Dharmacon (Lafayette, CO) ([Supplementary file 4](#supp4){ref-type="supplementary-material"}). siRNAs targeting RRAD (SASI_Hs01_00221658, SASI_Hs01_00221655, SASI_Hs01_00221652, SASI_Hs01_00221653) and shRNAs targeting TRIM27 (SHCLNG-NM_006510; TRCN0000280319 and TRCN0000011021) or a non-targeting control were purchased from Sigma (St. Louis, MO) ([Supplementary file 4](#supp4){ref-type="supplementary-material"}).

Expression plasmids {#s4-3}
-------------------

ZNF165 and ZNF446 cDNA was purchased in pDONR223 vectors from the DNASU Plasmid Repository (Tempe, AZ) and cloned into pLX302-V5 or pLX304-V5 lentiviral vectors, respectively, using the Gateway Cloning system (Thermo Fisher Scientific). psPAX2 and pMD2.G were gifts from Didier Trono (Addgene plasmids \#12260 and \#12259). SMAD3, SMAD4, and TRIM27 cDNA was obtained in pENTR221 vectors from the UT Southwestern (UTSW) McDermott Center for Human Genetics and subcloned into pCMV-HA or pCMV-myc (Clontech, Mountain View, CA) between SalI and NotI restriction sites. pCMV6-ZNF165-myc was obtained from Origene (Rockville, MD) (RC205600). The SCAN domain of pCMV6-ZNF165-myc was deleted using overlap extension PCR and verified by sequencing and western blot (primers listed in [Supplementary file 4](#supp4){ref-type="supplementary-material"}).

Generation of stable cell lines {#s4-4}
-------------------------------

Stable cell lines were generated through lentiviral-mediated transduction. HEK293T cells were co-transfected with the target gene vectors (pLX302 or pLX304) and lentiviral packaging plasmids (psPAX2 and pMD2.G). Virus conditioned media was collected 48 hr post transfection and used to infect target cells in the presence of polybrene. Selection with appropriate antibiotics was performed for 3 days following infection to generate stable populations. ZNF165-V5 or ZNF446-V5 expression was confirmed by RT-qPCR, western blotting, and immunofluorescence.

Western blotting and gene expression analysis {#s4-5}
---------------------------------------------

Western blotting was done as previously described ([@bib50]). RNA was isolated using the GenElute Mammalian Total RNA Miniprep Kit (Sigma), and 500 ng RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific) according to manufacturer's instructions. Taqman Real-Time PCR (Thermo Fisher Scientific) gene expression assays were run in technical duplicate to quantify expression on an Applied Biosystems QuantStudio 5 Real-Time PCR System. Relative expression values were calculated using the 2^-ΔΔCT^ method and the data were normalized to RPL27 values. Catalog numbers for Taqman probes used to measure gene expression can be found in [Supplementary file 4](#supp4){ref-type="supplementary-material"}.

Chromatin immunoprecipitation (ChIP) and sequencing (ChIP-seq) {#s4-6}
--------------------------------------------------------------

Cells were grown to \~90% confluency and crosslinked with 1% formaldehyde for 15 min at 37°C. Crosslinking was then quenched with 0.125 M glycine for 5 min at 4°C. Cells were washed twice with cold PBS and lysed in hypotonic buffer (5 mM PIPES pH 8, 85 mM KCl, 0.5% NP-40, 1 mM DTT). All buffers were supplemented with Complete Protease Inhibitor Cocktail (Sigma). Nuclei were pelleted at 2,000 rpm for 5 min and resuspended in lysis buffer containing 50 mM Tris pH 7.9, 1% SDS, 10 mM EDTA, and 1 mM DTT. Chromatin was sheared into 200--400 bp fragments using a Bioruptor sonicator (Diagenode), clarified by centrifugation at max speed for 10 min, and diluted (1:10) in buffer containing 20 mM Tris pH 7.9, 0.5% Triton X-100, 150 mM NaCl, 2 mM EDTA, and 1 mM DTT. Lysates were pre-cleared with Protein A/G agarose beads (Thermo Fisher Scientific) for 1 hr and, following removal of input material, incubated with appropriate antibodies overnight at 4°C. Protein A/G agarose beads blocked with BSA were then added to lysates for 2 hr, followed by one low salt wash (20 mM Tris pH 7.9, 125 mM NaCl, 0.05% SDS, 1% Triton X-100, 2 mM EDTA), one high salt wash (20 mM Tris pH 7.9, 500 mM NaCl, 0.05% SDS, 1% Triton X-100, 2 mM EDTA), a more stringent wash (10 mM Tris pH 7.9, 250 mM LiCl, 1% NP-40, 1% sodium deoxycholate, 1 mM EDTA), and a final wash in TE buffer (10 mM Tris pH 7.9, 1 mM EDTA). For western blotting of immunoprecipitated proteins, beads were boiled in 2X Laemmli sample buffer (containing 4% β-mercaptoethanol) for 5--10 min. Otherwise, chromatin was eluted from beads with 100 mM NaHCO~3~ and 1% SDS, and de-crosslinking was carried out overnight at 65°C. RNA and protein were digested with RNase A (3 μg/mL) and Proteinase K (50 μg/mL), respectively. DNA was purified using phenol/chloroform/isoamyl alcohol (25:24:1) and precipitated overnight with isopropyl alcohol at −20°C.

Libraries of ChIP DNA were prepared using the KAPA Hyper Prep Kit (KAPA Biosystems, Cape Town, South Africa) according to the manufacturer's instructions. Samples were multiplexed with Illumina adapters (NEB, Ipswich, MA) and 75 bp single end reads (\~50M per sample) were generated on an Illumina NextSeq 500 (UTSW McDermott Center Next Generation Sequencing Core). Raw reads were aligned to the human genome assembly (hg19) using Bowtie2 (ver 2.3.2) with the 'sensitive' parameters enabled, and the mapped read files were sorted and indexed with SAMtools (ver 1.6). BigWig files for visualization on the IGV genome browser ([@bib67]) were generated using DeepTools (ver 2.3.5). ChIP-seq was performed using biological duplicates for each sample. WHIM12 ZNF165-V5 ChIP-seq data was previously generated and is available under GEO accession GSE65937. All other ChIP-seq datasets have been deposited under GEO accession GSE130364.

ChIP-seq peak calling and annotation {#s4-7}
------------------------------------

Peaks were called using the HOMER (ver 4.9) findPeaks module with size and minimum distance parameters set to 150 bp and 370 bp, respectively. Target genes for each transcription factor were identified using GREAT version 3.0.0 ([great.stanford.edu](http://great.stanford.edu/public/html/)) with default parameters. The HOMER mergePeaks module was used to identify overlapping peaks with a size parameter of 1000 bp. Tag density plots were generated using the HOMER annotatePeaks module with size and bin size parameters set to 5000 and 5 bp, respectively. The same module with the genomeOntology parameter enabled was used to annotate the genomic regions associated with each factor. For heatmap generation, the HOMER annotatePeaks module was used to create matrix files, which were clustered with Cluster 3.0 and visualized with Java TreeView (ver 1.1.6r4). To identify motifs enriched at co-bound sites, motif discovery was performed with MEME (ver 5.1.1) in 'differential enrichment' mode. Motif density plots were generated using the HOMER annotatePeaks module with size and bin size parameters set to 5000 and 5 bp, respectively.

ChIP-qPCR {#s4-8}
---------

ChIP was performed as described above, and qPCR was carried out using SYBR green reagents in technical duplicates (Thermo Fisher Scientific) on an ABI QuantStudio 5 Real-Time PCR System. Three ten-fold dilutions were used to generate standard curves and the amount of ChIP DNA relative to corresponding input values (percent input) was calculated. SMAD3 enrichment was determined relative to IgG percent input values within the same treatment or condition. Primer sequences are listed in [Supplementary file 4](#supp4){ref-type="supplementary-material"}.

Proximity ligation assays {#s4-9}
-------------------------

Proximity ligation assays (PLAs) were performed using Duolink reagents (Sigma) according to manufacturer's instructions. Briefly, cells attached to glass coverslips were fixed with 3.7% formaldehyde for 15 min and then permeabilized with 0.5% Triton X-100 for 15 min. Blocking was performed for 1 hr at 37°C, and cells were incubated with appropriate antibodies overnight at 4°C. After washing, coverslips were incubated with PLUS (rabbit) and MINUS (mouse) secondary probes for 1 hr at 37°C. Ligation was performed for 30 min at 37°C, followed by rolling circle amplification for 100 min at 37°C. Coverslips were washed, mounted to glass slides in medium containing DAPI, and kept at 4°C. Cells were imaged using a Keyence BZ-X710 fluorescence microscope at 100x magnification and 5--10 regions of interest were captured on each coverslip. PLA signals were quantified using ImageJ by counting the average number of foci per nucleus in any given image.

Immunoprecipitation {#s4-10}
-------------------

For co-expression/co-immunoprecipitation studies, cells were lysed for 30 min on ice in non-denaturing lysis buffer (NDLB) containing 50 mM HEPES pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 25 mM β-glycerophosphate, 1 mM EDTA, 1 mM EGTA, 1 mM Na~3~VO~4~, 1 μg mL^−1^ pepstatin, 2 μg mL^−1^ leupeptin, 2 μg mL^−1^ aprotinin, and 10 μM bestatin. Lysates were clarified at 12,000 g for 10 min and pre-cleared with Protein A/G agarose beads for 1 hr at 4°C. Five percent of each lysate was set aside as input material and the remainder was immunoprecipitated with appropriate antibodies for 0.5--4 hr at 4°C. Protein A/G agarose beads blocked with 0.5% BSA were added in the final 30 min of immunoprecipitation. Beads were then washed three times in NDLB and once in NDLB containing 500 mM NaCl. For endogenous immunoprecipitation of ZNF165, \~2×10^8^ cells were collected and lysed in a hypotonic buffer (5 mM PIPES pH 8, 85 mM KCl, 0.5% NP-40) supplemented with Complete Protease Inhibitor Cocktail (Sigma) for 20 min. Nuclei were pelleted at 2,000 rpm for 5 min and resuspended in RIPA buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.5% SDS, 25 mM β-glycerophosphate, 1 mM EDTA, 1 mM EGTA, 1 mM Na~3~VO~4~) supplemented with Complete Protease Inhibitor Cocktail. Nuclear lysis was facilitated by gentle agitation at 4°C with intermittent sonication (5--10 pulses at 5 s each using a Fisher Scientific Model 60 Sonic Dismembrator). Lysates were clarified at 16,000 g for 10 min, concentrated to a volume of 1--2 mL, and pre-cleared with Protein A/G agarose beads for 1 hr at 4°C. Five percent of each lysate was set aside as input material and the remainder was subjected to immunoprecipitation overnight at 4°C. The next day, Protein A/G agarose beads blocked with BSA were added to lysates for 2 hr, followed by four washes in a buffer containing 50 mM HEPES pH 7.4, 150 mM NaCl, 1% Triton X-100, 25 mM β-glycerophosphate, 1 mM EDTA, 1 mM EGTA, 1 mM Na~3~VO~4~, and Complete Protease Inhibitor Cocktail. Immunoprecipitated proteins were eluted in 2X Laemmli sample buffer (containing 4% β-mercaptoethanol) by boiling for 5--10 min.

Soft agar assays {#s4-11}
----------------

4 × 10^3^ SUM159 or MCF7 cells were trypsinized, counted, and resuspended in 0.366% Bacto agar in complete medium and seeded on a layer of solidified 0.5% Bacto agar in 6-well plates 48 hr post-transfection. After solidification, another layer of complete medium containing 2X FBS was added. Cells were grown for 14 days (fed every 3 days) and then stained with 0.05% crystal violet in phosphate-buffered saline (PBS) overnight. Images were taken using a LEICA MZ75 stereomicroscope at a magnification of 6.3X and colony number was quantified using ImageJ software.

Tumor expression and patient survival analysis {#s4-12}
----------------------------------------------

Normal/tumor expression data for ZNF446 and TRIM27 was generated by the TCGA Research Network (<https://www.cancer.gov/tcga>) and visualized with Oncomine and UALCAN, respectively ([@bib66]; [@bib11]). Survival analysis was performed using Kaplan Meier plotter ([@bib25]). For ZNF165, expression data was bifurcated using the upper quartile. For RRAD expression data was bifurcated using median and lower tertile for OS and DMFS, respectively. For ZNF446, expression was based on median values. Hazard ratios and p-values were calculated using the logrank test.

Human breast tissue immunohistochemistry (IHC) {#s4-13}
----------------------------------------------

Normal breast and TNBC tissues were obtained with informed consent from the UTSW Tissue Management Shared Resource (TMSR) in compliance with the UTSW Internal Review Board committee. TRIM27 IHC was optimized and performed by the TMSR according to internal protocols using the Dako Autostainer Link 48 system. Quantification of nuclear TRIM27 signal was performed using IHC Profiler (ImageJ) according to the developer's guidelines ([@bib94]).

Orthotopic xenografts {#s4-14}
---------------------

SUM159T-Luciferase cells (5 × 10^5^) stably expressing TRIM27 shRNAs or a non-targeting hairpin were injected in the mammary fat pad of 10 week old female NOD.Cg-*Prkdc^scid^ Il2rg^tm1Wjl^*/SzJ (NSG) mice obtained from the Jackson Laboratory as previously described ([@bib97]). Ten mice per condition were tested. Eight mice allowed for the comparison of the mean values of two different samples (Control and Test) with a standard deviation value of up to 60% of the difference between the means and a power of 0.8 using a two−sample t test. Ten mice were used to account for possible technical problems in handling samples after the mouse is sacrificed, the need to prematurely sacrifice mice because of an adverse response to surgical or non−surgical procedures, illness, or complete failure of tumor growth. Mice were assigned to groups randomly. Tumors were measured weekly using a digital caliper and volume (V) was calculated using the following formula: V = (Length x (Width^2^))/2. Starting four weeks post injection, tumors were measured weekly with bioluminescent imaging (BLI). At six weeks post injection, mice were sacrificed after obtaining final BLI measurements. These studies were conducted in accordance with a UT Southwestern Institutional Animal Care and Use Committee (IACUC) approved protocol.

Statistical analysis {#s4-15}
--------------------

Graphpad Prism (Graphpad Software) was used to perform statistical analyses. Data were assessed by one or two-tailed, unpaired t-tests or Mann-Whitney, or hypergeometric distribution. P-values less than 0.05 were considered significant. Biological replicates were considered to be experiments performed on distinct samples, while technical replicates were considered identical samples run in parallel.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

This manuscript describes how the DNA-binding protein ZNF165, which is normally expressed in testis, is reactivated and co-opted in triple-negative breast cancer (TNBC) to promote tumor growth. Employing molecular studies and phenotypic assays (both in cell lines and mouse xenografts) the authors identified a TGFβ-SMAD3/4-ZNF165-ZNF446-TRIM27 axis through which a subset of genes become dysregulated to promote cancer progression. These results provide a foothold towards targeting normally-intractable TNBC through this novel regulatory complex.

**Decision letter after peer review:**

\[Editors' note: the authors submitted for reconsideration following the decision after peer review. What follows is the decision letter after the first round of review.\]

Thank you for submitting your work entitled \"The testis protein ZNF165 is a SMAD3 cofactor that coordinates oncogenic TGFβ signaling in triple-negative breast cancer\" for consideration by *eLife*. Your article has been reviewed by four peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Senior Editor. The reviewers have opted to remain anonymous.

Reviewers discussed the strengths and shortcomings of the current manuscript. While they appreciated the overall good quality of the work and the interesting area of research (i.e. role of testes-specific proteins in TGF β signaling and cancer), in the end they agreed not to invite a revised manuscript at this stage. Reviewers agreed that the first part of the paper did not provide enough new knowledge over a previous publication by the same team (Maxfield et al., 2015), and that the second part of the paper, which describes novel findings, was of lesser quality and more superficial (see appended reviews for specific concerns). After discussion, reviewers agreed that the experiments required to elevate the second part of the paper would require significantly more time than the usual two month period allowed at *eLife*. Therefore, they decided to recommend a Rejection of the current manuscript, while encouraging the authors to employ the constructive criticism to improve the manuscript, and potentially consider a new submission to *eLife* in the future.

Reviewer \#1:

The manuscript by Gibs et al. demonstrates a novel role for the testes-specific DNA-binding protein ZNF165 in control of a subset of TGFβ/SMAD target genes in TNBC. The data demonstrates co-occupancy and co-regulation of some SMAD3 targets in TNBC cells, including genes required for anchorage-independent growth (e.g. RRAD). Mechanistically, the paper also describes other cofactors required for control of a subset of SMAD targets, including ZNF446 and TRIM27. Overall, the manuscript is (mostly) well written with well supported conclusions, but it relies heavily on in vitro cell-based models with no support for this novel mechanism in mouse models of TNBC or available data from human tumors.

Are ZNF165 and its binding partners ZNF446 and TRIM27 required for growth in xenograft or PDX models? What is the clinical behavior of TNBCs that express high or low levels of these three factors? (e.g. prognosis, 5 year survival). What is the relationship between expression of these three factors and TGFβ signatures in TNBC? In sum, the manuscript falls short of making a compelling case for the mechanism described to be relevant in the clinical setting, something that could be addressed with additional experiments and analyses of existing datasets.

Also, the passage of the manuscript about characterization of ZNF446 and TRIM27 is a bit confusing, showing data for interaction with SMAD3 and SMAD4, respectively. Does ZNF446 interact with SMAD4? Does TRIM27 interact with SMAD3? The authors seem to have all reagents to complete the proximity ligation assays and co-immunoprecipitation to answer these questions.

Reviewer \#2:

Gibbs et al. demonstrate here that the Cancer-Testes antigen ZNF165 is a co-factor for SMAD3 in regulation of TGF-β signaling in TNBC. Evidence based on genomic binding profiles is compelling. The linking to gene expression analyses of these genomic binding data identify a set of genes that have both ZNF165 and SMAD3 binding sites AND are regulated by TGF-β. So far, so good. The authors then select a few of these target genes for functional analyses. This is a less compelling part of the manuscript. For instance, the authors show that knockdown of RRAD impairs soft agar growth of SUM159 cells, but fail to address whether 2D growth of these cells is equally affected, as appears the case in WHIM12 cells. A quick survey of the Broad Institute project Achilles shows that knockdown of RRAD is not particularly essential in breast cancer compared to a number of other cancers (https://depmap.org/portal/gene/RRAD?tab=dependency). Yet the authors argue that their functional data provide evidence that \"RRAD is a relevant transcriptional target of TGFβ in TNBC, as evidenced by its essentiality for anchorage independent growth\".

This statement implies that in all cells in which RRAD is an essential gene, its expression is driven by TGF-β and in the absence of TGF-β, knockdown of RRAD has little effect (due to low expression). These conclusions are in my view not supported by the data presented.

I am fully on board with the notion that ZNF165 is a SMAD3 co-factor and involved in TGF-β mediated transcriptional responses. The presence of ZNF446 and TRIM27 in these complexes is also well-supported. In my view, the authors should refrain from over-interpreting these data. There is no compelling evidence in this manuscript that these cancer-testis antigens are key components of the switch from tumor suppressive to oncogenic signalling by TGF-β.

Reviewer \#3:

In general, I find that the topic of this paper is inherently of high interest. CT antigens are known to occur in tumors, but mechanistic details have not been worked out for most of them. Add to that the fact that this paper is trying to address this gap in triple-negative breast cancer cells-which elude common treatments-the findings from such a study will have major consequences on the cancer field. However, I find the paper slightly shaky in two areas: the importance of Figure 2C to the overall conclusions, and the frequent use of tagged proteins and overexpression to draw conclusions.

Specific concerns:

1\) It would be interesting to know what percentage of SMAD3 binding sites are promoters, and compare that with the analogous percentage from ZNF165:SMAD3 co-bound sites. In other words, are co-bound sites more/less enriched in terms of promoter regions vs all SMAD3 binding sites? The authors already have the datasets, and so will just have to look.

2\) Do SMAD3 and ZNF165 have binding sites on each other\'s genetic regions? This is assumed not to be the case, but should be explicitly addressed because it directly affects the interpretation of scatter plots like Figure 2B. This is also the case for other similar plots i.e. Figure 4C and Figure 5C.

3\) I find Figure 2C quite problematic in terms of interpretation, and definitely not as straightforward as the authors put it in the text. In terms of the raw magnitude of relative expression (i.e. y-axis of scatter plot), the siZNF165 condition is behaving as you would expect from Figure 2B. However, the trend increase/decrease in expression is sometimes not what you would expect from Figure 2B: e.g. SMURF2, according to Figure 2B, is repressed both by SMAD3 and ZNF165, but its expression increases with increased exposure to TGFβ (and presumably increased SMAD3 signaling), making this panel inconsistent with Figure 2B.

4\) Most of the co-immunoprecipitation experiments and the proximity ligation assays were done with tagged constructs and overexpression. It is well-known that a major caveat of overexpression is promiscuous binding at non-physiological concentrations. The authors already show in Figure 5E that they are able to carry out a proximity ligation assay with antibodies towards endogenous proteins. Why not do the same for the other PLA experiments and co-IP experiments?

5\) In the PLA experiments, control experiments with the TGFβ inhibitor (SB-431542) should always be done. This is only done in Figure 3.

6\) In Figure 3E, technically, what is shown is that there is proximal interactions between two proteins. But whether this is mediated by DNA binding (which is the assumption here) is not explicitly tested. It would be good if a PLA experiment can be done with a ZNF165 version that does not bind DNA, to show that these interactions are due to ZNF165\'s ability to bind DNA binding sites, and not because ZNF165 can bind to SMAD3 by itself. This is also the case for other PLA experiments in the study.

Reviewer \#4:

The work of Gibbs et al. dissects a transcriptional regulator complex, which is formed in triple negative breast cancer (TNBC) cell lines. The authors have previously identified a major player in this regulatory process (ZNF165) and are now describing that:

1\) Binding sites of ZNF165 and SMAD3 largely overlap and found a common GC-rich element

2\) ZNF165 acts upstream of TGF-β sensitive genes

3\) SCAND1 and ZNF446 form a complex with ZNF165

The work is largely focussed on dissecting the individual interaction partners and network regulation and touches upon effects in cell growth.

My major concerns are that:

1\) much of the novelty has been already published in the previous study of the group (Maxfield, 2015)

2\) signalling cascades or proposed working model should highlight what is known and what is the new contribution (especially with regards to TGF-β), how this relates to early and late breast cancer settings and how the observations fit the testis-specific regulatory program (perhaps a model summarizing the work can be added to the last figure).

Other concerns:

1\) Add survival analysis of the factors mentioned (TNBC vs. non- TNBC, early and late stage using TGCA data) that will support the speculative roles in early and late cancer responses

2\) Motif enrichment (Figure 1G): similar motifs has been identified (PB0164.1 for SMAD3). I therefore question whether the motif is a genuine ZNF165 binding motif. It appears rather common for many SMAD3 binding sites.

3\) How does the TGF-β specific response influence the readout? Why were 16h chosen (Figure 2A) when much of the responses happen already within the first 2h (Figure 2C)?

\[Editors' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for submitting your article \"The testis protein ZNF165 is a SMAD3 cofactor that coordinates oncogenic TGFβ signaling in triple-negative breast cancer\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Kevin Struhl as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as *eLife* papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.

Summary:

The work of Gibbs et al. describes how the DNA-binding protein ZNF165, which is normally expressed in testis, is "re-activated" in triple-negative breast cancer (TNBC) to promote tumor growth. Employing molecular studies and phenotypic assays (both in cell lines and mouse xenografts) the authors identified a TGFβ-SMAD3/4-ZNF165-ZNF446-TRIM27 axis through which a subset of genes become dysregulated to promote cancer progression.

The current, revised version of the manuscript is much improved relative to the original submission. Key improvements and additions include new evidence of physical interaction between the various combinations of testis-specific transcription factors and their cofactors, new ChIP-seq datasets reinforcing the interplay between these factors on chromatin, additional analysis of human tumor gene expression data, and TNBC xenograft data showing a requirement for TRIM27 for cancer cell proliferation. The authors have made a commendable work at addressing the major and minor concerns raised by reviewers of the original manuscript.

Overall, the reviewers agreed that the manuscript merits publication in *eLife* after addressing the points below. The topic of the paper was deemed of high interest in general, because through this work, the authors provide a foothold towards targeting normally-intractable TNBC through the testis-specific DNA-binding protein ZNF165. Additional value was found in the interesting biology described, whereby ZNF165, when expressed ectopically, can nucleate the assembly of a new transcription regulatory complex in cancer cells.

Revisions:

1\) Whenever possible, please create VENN diagrams that are proportional in size to comparisons made.

2\) Similar to Figure 1---figure supplement 1B, please add a VENN diagram for ZNF165 (at least for WHIM12 and SUM159 cells for which data are presented in this manuscript)

3\) Please explain why those 118 ZNF165 and SMAD3 co-bound regions (Results paragraph one) were inspected further. Next to which genes do they reside? Are these the 65 TGFβ-responsive genes mentioned in Results paragraph two and in Figure 2---figure supplement 1A? If so, please refer to them in the text. If not, please add a supplementary table with those gene names.

4\) Figure 1F: do the co-occupied sites correspond to the 118 sites mentioned above? What is the total number of SMAD3 binding sites? Please add an \"n=XX\" in the figure legend.

5\) Please provide a supplementary table containing the genes used in the gene set enrichment analysis (Figure 1---figure supplement 1D)

6\) Add a label (roman letter) for each of the quadrants as discussed in the manuscript (Figure 2A, Figure 6D)

7\) Mention previously that the role of SMURF2 was previously addressed (Maxfield et al., 2015; Ohashi et al., 2005) either in paragraph two of subsection "ZNF165 and SMAD3 cooperate to modulate TGFβ-responsive gene expression" or in the Discussion.

8\) Subsection "ZNF165 physically associates with SMAD3 in a TGFβ-dependent manner": Comment on that ZNF165 does not regulate the SMAD3 and SMAD4 gene loci.

9\) Move Figure 5C/D to supplements. It is good to show that the peaks are overlapping in part but the actual genes (Figure 5I) are more relevant.

10\) Materials and methods:

a\) Ideally add lot number of the antibodies used for the ChIP experiments.

b\) Add machine name for the IP (also a Bioruptor?)

11\) The main story is about how the nucleating of a new complex that is capable of tuning transcriptional activity, but most of the measurements for such \"transcriptional\" activity is assayed by steady state mRNA levels, e.g. qRT-PCR of target genes, after siRNA knockdown of factors of interest. In the case of Figure 2A, this is still believable because the data in panel A is at least supported by the H3K27ac ChIP in panels E and F. However, in other parts of the paper, e.g. Figure 5J, changes in expression levels (as measured by qRT-PCR) is taken to be due to transcriptional changes-which is not a given- as any post-transcriptional effects that are caused by the siRNA knockdowns would also lead to changes in steady state expression levels. The same point applies to Figure 6E. It is important then for the authors to introduce a clear disclaimer stating that post-transcriptional effects cannot be discarded, and that a fraction of the genes altered by the siRNA knockdowns could be non-transcriptional targets.

12\) Figure 1---figure supplement panel E: The labelling of the two lines appear to be flipped. According to the text, patients with high ZNF165 expression are associated with greater metastatic potential, but this is inconsistent with the graph shown in panel E, as currently labelled.

13\) Figure 2A: Quadrants are not labelled, but are referred to in the text.

14\) \"anchorage-independent growth using soft agar assays\"... The figure panel referred to here should just be Figure 6---figure supplement panel E only. Panel D in the supplement refers to something else, and it is unclear what panel D is trying to show.

10.7554/eLife.57679.sa2

Author response

\[Editors' note: the authors resubmitted a revised version of the paper for consideration. What follows is the authors' response to the first round of review.\]

> Reviewers discussed the strengths and shortcomings of the current manuscript. While they appreciated the overall good quality of the work and the interesting area of research (i.e. role of testes-specific proteins in TGF β signaling and cancer), in the end they agreed not to invite a revised manuscript at this stage. Reviewers agreed that the first part of the paper did not provide enough new knowledge over a previous publication by the same team (Maxfield et al., 2015), and that the second part of the paper, which describes novel findings, was of lesser quality and more superficial (see appended reviews for specific concerns). After discussion, reviewers agreed that the experiments required to elevate the second part of the paper would require significantly more time than the usual two month period allowed at eLife. Therefore, they decided to recommend a Rejection of the current manuscript, while encouraging the authors to employ the constructive criticism to improve the manuscript, and potentially consider a new submission to eLife in the future.

The key concern of the original manuscript was a lack of robust and in-depth analysis of the novel findings. We believe that the revised manuscript contains a more comprehensive and detailed study responding to the following points brought up by the reviewers:

1\) Multiple reviewers requested evidence of endogenous interactions between members of the transcriptional complex. We now present proximity ligation assays demonstrating endogenous associations between ZNF165 and SMAD3, ZNF165 and SMAD4, ZNF446 and SMAD3, ZNF446 and SMAD4, TRIM27 and SMAD3, and TRIM27 and SMAD4. We also present endogenous immunoprecipitations of ZNF165 and ZNF446. Together, we think that these assays present a compelling case that these proteins form a complex within intact cells, a novel observation that has important implications for understanding TGFβ signaling in TNBC.

2\) To further reinforce the functional relevance of the ZNF165- SMAD3-ZNF446 interaction, we generated ChIP-seq datasets for ZNF446. This dataset demonstrates co-occupancy of all three of these factors on chromatin and reinforces the notion that ZNF165 and SMAD3 form a complex with ZNF446 to modulate TGFβ-induced transcription. Notably, a prior attempt from another group to define ZNF446 binding sites indicated that either ZNF446 lacked widespread DNA binding activity or was unable to bind in that context2. Thus, the dataset generated herein provides the first indepth analysis of ZNF446 genomic occupancy and, along with the associated protocols, should provide essential information for future functional analysis of ZNF446 in different contexts.

3\) The initial manuscript had limited information regarding the clinical relevance of the transcriptional complex in human tumors. To mitigate this concern, we now present multiple lines of evidence that these factors are associated with poor outcome. First, we demonstrate that ZNF165 correlates with a reduced distant metastasis free survival in breast cancer. In addition, we find that ZNF165 expression is significantly associated with an EMT gene expression signature, a hallmark of tumor cells that exhibit oncogenic TGFβ signaling. Second, we show that ZNF446 is elevated in breast cancer and trends with reduced overall survival. Third, we find that TRIM27 is also elevated in TNBC and that its nuclear localization is associated with tumorigenic state. Fourth, expression of RRAD, a target gene of the ZNF165 transcriptional complex, exhibits a dramatic association with poor outcome in mesenchymal breast cancers (enriched for TNBC). However, we observed no association with patient outcome in ER+ breast tumors, where TGFβ signaling is tumor-suppressive. Finally, to test the relevance of the transcriptional complex in vivo, we depleted TRIM27 from TNBC cells and found a significant reduction in tumor growth at the orthotopic site in mice.

4\) We have also addressed a number of the minor concerns of the reviewers including the removal of Panel 2C, additional statistical analysis of the ChIP-seq data sets, and reduction in overinterpretations regarding a role for this complex in switching the TGFβ signaling output from tumor-suppressive to oncogenic.

\[Editors' note: what follows is the authors' response to the second round of review.\]

> Overall, the reviewers agreed that the manuscript merits publication in eLife after addressing the points below. The topic of the paper was deemed of high interest in general, because through this work, the authors provide a foothold towards targeting normally-intractable TNBC through the testis-specific DNA-binding protein ZNF165. Additional value was found in the interesting biology described, whereby ZNF165, when expressed ectopically, can nucleate the assembly of a new transcription regulatory complex in cancer cells.
>
> Revisions:
>
> 1\) Whenever possible, please create VENN diagrams that are proportional in size to comparisons made.

Size adjustments have been made to the VENN diagrams for the following: Figure 1---figure supplement 1 (panels A, B, C, and E), Figure 5 (panels C, D, and I), Figure 5---figure supplement 1 (panels B, C, and D).

> 2\) Similar to Figure 1---figure supplement 1B, please add a VENN diagram for ZNF165 (at least for WHIM12 and SUM159 cells for which data are presented in this manuscript)

A VENN diagram displaying the overlap between ZNF165 ChIP-seq peaks identified in WHIM12 and SUM159 cells has been added to the Figure 1 supplement (Figure 1---figure supplement 1A). In addition, VENN diagrams showing the overlap between ZNF165 and SMAD3 ChIP-seq peaks in both WHIM12 and SUM159 cells have also been added here (Figure 1---figure supplement 1B and 1C) for additional clarity.

> 3\) Please explain why those 118 ZNF165 and SMAD3 co-bound regions (Results paragraph one) were inspected further. Next to which genes do they reside? Are these the 65 TGFβ-responsive genes mentioned in Results paragraph two and in Figure 2---figure supplement 1A? If so, please refer to them in the text. If not, please add a supplementary table with those gene names.

The 118 co-bound regions are those found in WHIM12 cells bound by both ZNF165 and SMAD3 as identified by ChIP-seq peak overlap. This point is now made more clearly in the text (Results paragraph two) with the inclusion of a Venn diagram (Figure 1---figure supplement 1B) and a supplementary table (Supplementary file 1) as requested. These 118 co-bound sites were used solely to identify any motifs unique to co-bound regions in the WHIM12 cells. These are not the 65 TGFβ-responsive genes that we used to identify co-regulated genes.

> 4\) Figure 1F: do the co-occupied sites correspond to the 118 sites mentioned above? What is the total number of SMAD3 binding sites? Please add an \"n=XX\" in the figure legend.

The co-occupied sites in Figure 1F correspond to the 118 overlapping peaks described in Figure 1F. For full clarification on this and point 3, we now refer to these as "ZNF165-SMAD3 co-bound sites" in Figure 1F and in the text. As requested, the legend for figure 1F has now been updated to read: "Pie charts displaying the distribution of genomic features bound by ZNF165-SMAD3 (n=118) or only SMAD3 (n=27,979) in WHIM12 cells."

> 5\) Please provide a supplementary table containing the genes used in the gene set enrichment analysis (Figure 1---figure supplement 1D)

Supplementary file 2 has been created with the genes used in the gene set enrichment analysis, along with their corresponding enrichment values used to generate Figure 1---figure supplement 1G. The table is referenced within the figure legend for Figure 1---figure supplement 1G.

> 6\) Add a label (roman letter) for each of the quadrants as discussed in the manuscript (Figure 2A, Figure 6D)

Labels for the quadrants in Figure 2A and Figure 6D have been added. In addition, the text was modified to call out the appropriate quadrants mentioned for Figure 6D (subsection "TRIM27 is essential for ZNF165 transcriptional activity and tumor growth in vivo").

> 7\) Mention previously that the role of SMURF2 was previously addressed (Maxfield et al., 2015; Ohashi et al., 2005) either in paragraph two of subsection "ZNF165 and SMAD3 cooperate to modulate TGFβ-responsive gene expression" or in the Discussion.

We now mention that the role of SMURF2 was previously addressed and that, together with the data presented in this study, ZNF165 and SMAD3 cooperate to relieve negative feedback within the TGFβ pathway via repression of SMURF2.

> 8\) Subsection "ZNF165 physically associates with SMAD3 in a TGFβ-dependent manner": Comment on that ZNF165 does not regulate the SMAD3 and SMAD4 gene loci.

We have added a comment at the end of the section describing Figure 3 that ZNF165 does not regulate the SMAD3 or SMAD4 gene loci. This is based on inspection of the ChIP-seq datasets presented in this study and our previous work, as referenced.

> 9\) Move Figure 5C/D to supplements. It is good to show that the peaks are overlapping in part but the actual genes (Figure 5I) are more relevant.

Figure 5C and 5D have been moved to the supplement (Figure 5---figure supplement 1B and 1C). In addition, VENN diagrams of target gene overlaps between ZNF165 and ZNF446 have been added to Figure 5 (panels C and D). The main text has been updated to reflect these changes.

> 10\) Materials and methods:
>
> a\) Ideally add lot number of the antibodies used for the ChIP experiments.
>
> b\) Add machine name for the IP (also a Bioruptor?)

Lot numbers for antibodies used in ChIP experiments have been added to the Materials and methods section. Additionally, the name of the sonicator used for the endogenous IP experiment has been added to the Materials and methods section.

> 11\) The main story is about how the nucleating of a new complex that is capable of tuning transcriptional activity, but most of the measurements for such \"transcriptional\" activity is assayed by steady state mRNA levels, e.g. qRT-PCR of target genes, after siRNA knockdown of factors of interest. In the case of Figure 2A, this is still believable because the data in panel A is at least supported by the H3K27ac ChIP in panels E and F. However, in other parts of the paper, e.g. Figure 5J, changes in expression levels (as measured by qRT-PCR) is taken to be due to transcriptional changes-which is not a given- as any post-transcriptional effects that are caused by the siRNA knockdowns would also lead to changes in steady state expression levels. The same point applies to Figure 6E. It is important then for the authors to introduce a clear disclaimer stating that post-transcriptional effects cannot be discarded, and that a fraction of the genes altered by the siRNA knockdowns could be non-transcriptional targets.

We thank the reviewers for bringing this important concern to our attention and we fully agree. As requested, we have added a sentence within the Discussion section pointing out this caveat.

> 12\) Figure 1---figure supplement panel E: The labelling of the two lines appear to be flipped. According to the text, patients with high ZNF165 expression are associated with greater metastatic potential, but this is inconsistent with the graph shown in panel E, as currently labelled.

The point of this plot was to demonstrate the early drop-off in distant metastasis free survival (up to 150 months) in the ZNF165-high patients. At later time points, these lines do appear flipped but only represent relatively few remaining patients. Importantly, the ZNF165- high population having a greater metastatic potential is best reflected in the hazardratio of 1.4 which is calculated on the entire data set (p=0.004).

> 13\) Figure 2A: Quadrants are not labelled, but are referred to in the text.

Quadrants have been added to the figure panels (see above).

> 14\) \"anchorage-independent growth using soft agar assays\"... The figure panel referred to here should just be Figure 6---figure supplement panel E only. Panel D in the supplement refers to something else, and it is unclear what panel D is trying to show.

The purpose of Figure 6---figure supplement 1D was to demonstrate that there is a mild defect observed in 2-dimensional growth of TNBC cell lines following TRIM27 loss, according to DepMap. In contrast, when cells are placed in the more stressful soft-agar environment, we observed a dramatic growth defect. To avoid confusion, we have removed panel D from the figure supplement as these data do not add any appreciable information to the manuscript. We appreciate the reviewers bringing this point to our attention. The text has been updated to reflect this change.
